BioSig’s Cardiac Signal Processing Technology To Be Featured at Kansas City Heart Rhythm Symposium 2022
August 17 2022 - 8:15AM
BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the
"Company"), a medical technology company advancing
electrophysiology workflow by delivering greater intracardiac
signal fidelity through its proprietary signal processing platform,
today announced its participation in the Kansas City Heart
Rhythm Symposium, being held on August 20-21, 2022. The
Company’s PURE EP ™ System, a non-invasive device that aims
to drive procedural efficiency and efficacy in cardiac
electrophysiology, will be highlighted in a physician presentation
during the symposium.
The presentation, titled, “Going Back to Old School - Leveraging
EGMs to Improve Efficacy, Safety of Ablation” will be conducted
during a symposium session beginning at 12:30 PM ET on Sunday,
August 21, 2022. Hicham El Masry. M.D., a Cardiac
Electrophysiologist at Mayo Clinic’s Arizona Campus, will discuss
the clinical advantages of the PURE EP™ System and the impact the
technology has made on his electrophysiology (EP) practice and
procedural workflow.
During the event, the Company’s clinical and commercial teams
will host product demonstrations that will showcase the latest
advancements and software features of its PURE EP ™ System. The
Company will also provide an update on developments in its clinical
pipeline.
“We are looking forward to returning to KCHRS, with the latest
advancements of the PURE EP™ System that have been demonstrated and
featured by one of our earliest adopters,” commented Gray Fleming,
Chief Commercialization Officer, BioSig Technologies, Inc. “We
would like to thank Dr. Lakkireddy for allowing us to be a part of
such an important meeting and Dr. El Masry for representing our
technology at the symposium.”
To register for the event,
please click here.
BioSig recently announced the commencement of a
physician-initiated research protocol that will analyze the signals
acquired by its PURE EP™ System during Radiofrequency (RF)
ablation. Led by Dhanunjaya DJ Lakkireddy, MD, Medical Director for
the Kansas City Heart Rhythm Institute, the single center
study underway at Overland Park Regional Medical Center, is
officially registered with clinicaltrials.gov [NCT05464537], and
includes 30 participants with paroxysmal atrial fibrillation (AF)
undergoing pulmonary vein isolation (PVI).
About KCHRS 2022The Kansas City Heart Rhythm
Symposium is an EP-focused medical education event for the
neighboring four state regions. A variety of topics will provide
specialists and generalists an update on the evolution of disease
processes, diagnostic tools, therapeutic strategies and ethical
issues in the advancement of patient care. To learn more
visit, www.kchrs.com.
About BioSig Technologies
BioSig Technologies is a medical technology company
commercializing a proprietary biomedical signal processing platform
designed to improve signal fidelity and uncover the full range of
ECG and intra-cardiac signals (www.biosig.com).
The Company's first product, PURE EP™ System, is a novel signal
processing and acquisition platform designed to extract advanced
diagnostic and therapeutic data that enhances physician workflow
and increases throughput. PURE EP™ was engineered to address the
limitations of existing EP technologies by empowering physicians
with superior signals and actionable insights.
The Company is in a national commercial launch of the PURE EP™
System. The technology is in regular use in some of the country’s
leading centers of excellence, including Mayo Clinic, and
Texas Cardiac Arrhythmia Institute at St. David’s Medical
Center.
Clinical data acquired by the PURE EP™ System in a multi-center
study at centers of excellence including Texas Cardiac Arrhythmia
Institute at St. David’s Medical Center was recently
published in the Journal of Cardiovascular Electrophysiology and is
available electronically with open access via the Wiley Online
Library. Study results showed 93% consensus across the blinded
reviewers with a 75% overall improvement in intracardiac signal
quality and confidence in interpreting PURE EP(T.M.) signals over
conventional sources.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) market conditions and the
Company’s intended use of proceeds, (ii) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (iii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iv)
difficulties in obtaining financing on commercially reasonable
terms; (v) changes in the size and nature of our competition; (vi)
loss of one or more key executives or scientists; and (vii)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website
at http://www.sec.gov. The Company assumes no obligation to
publicly update or revise its forward-looking statements as a
result of new information, future events or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2024 to May 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From May 2023 to May 2024